FTC Complaint Against the Three Largest Pharmacy Benefit Managers
September 2024
The recent Federal Trade Commission (FTC) complaint against the three largest pharmacy benefit managers (PBMs) has brought critical issues surrounding insulin pricing and patient access to the forefront. Crystal Clear Rx remains dedicated to promoting transparency and advocating for a pass-through model that benefits patients, plans, and employers alike. The FTC’s case highlights the need for a fundamental shift in how PBMs operate, and it’s a pivotal moment for stakeholders across the healthcare spectrum.
The Case at a Glance: FTC View Of a Broken System
The FTC’s complaint accuses major PBMs and their affiliated group purchasing organizations of manipulating formularies to favor higher-rebate insulin products over those with lower list prices. This practice has led to skyrocketing costs for patients despite the availability of more affordable options. The complaint underscores how PBMs’ pursuit of rebates has distorted the market, prioritizing profit over patient care.
Since 2012, PBM practices have significantly changed. Formularies that once covered most approved medications have become restrictive, with coverage decisions heavily influenced by rebate potential rather than clinical efficacy or affordability. This has not only impacted insulin pricing but has also had a ripple effect across the pharmaceutical industry.
How Do Rebates Affect You?
The FTC’s focus on insulin pricing illustrates a broader issue affecting many other medications. While rebates were originally intended to lower costs, they have instead contributed to higher out-of-pocket expenses for patients. For patients, the higher list price means paying more at the pharmacy counter, even if their insurance plan covers a portion of the costs. For employers and plan sponsors, this opaque system can lead to higher overall healthcare expenses and misaligned incentives that do not necessarily benefit their workforce or beneficiaries.
The Push for Transparency and Reform
The FTC’s complaint is part of a broader movement toward transparency and fairness in the pharmaceutical and PBM industries. Legislative efforts, such as the Lower Costs, More Transparency Act and proposals to “delink” PBM compensation from drug pricing, reflect a growing consensus that the current system needs reform. These changes aim to curb the influence of rebates and promote a more straightforward negotiation process based on net pricing rather than inflated list prices.
Key Points to Watch:
-
- Potential Impact of FTC’s Action: If successful, the FTC’s administrative complaint could set a precedent, leading to reduced list prices for insulin and potentially other drugs. This would directly benefit patients by lowering out-of-pocket costs and improving access to essential medications.
- Legislative Developments: With bipartisan support for PBM reform, there is hope for more comprehensive legislation that addresses the root causes of high drug prices. This could include measures to increase transparency in PBM practices and limit the influence of rebates on formulary decisions.
- Changes to PBM Business Models: As scrutiny increases, PBMs may be forced to adopt more transparent, pass-through models. This would align incentives more closely with patient health outcomes rather than maximizing rebates and fees. However, while larger PBMs may change the model, time and time again has shown us that they will find other ways to maintain their profit margins.
What This Means for Our Clients
At Crystal Clear Rx, we advocate for a transparent pass-through PBM model that ensures all rebates and discounts are fully disclosed and passed back to the plan sponsors. Our model eliminates the conflicts of interest inherent in traditional PBM arrangements and provides our clients with clear, actionable data to make informed decisions.
With the ongoing scrutiny of PBM practices, now is the time for plan sponsors to evaluate their current PBM contracts and consider alternative models that prioritize transparency and cost-efficiency. Whether you are renegotiating your current PBM agreement or exploring new options, we are here to provide expert guidance and support.
Stay Informed with Crystal Clear Rx
As this case progresses and new developments emerge, we will continue to keep you informed about what it means for your organization and your members. For the latest updates and in-depth analysis, contact us directly to discuss how these changes may impact your PBM strategy.
Together, we can navigate these challenges and advocate for a more transparent and equitable healthcare system.
Crystal Clear Rx is committed to providing our clients with comprehensive insights and support. Contact us today to learn more about our transparent PBM consulting services and how we can help you optimize your pharmacy benefits.
Authored: Tito Chavez-Nguyen
Recent Newsletters
Managing the Costs of GLP-1 Drugs: A Strategic Approach
Managing the Costs of GLP-1 Drugs: A Strategic Approach June 2024At Crystal Clear Rx (CCRx), we understand that the rising popularity and costs of GLP-1 drugs have raised many questions and concerns. We aim to provide clarity and guidance on managing these expenses...
What Is The Right Copay Strategy?
What Is The Right Copay Strategy? January 2024Crystal Clear Rx clients know that effectively managing the pharmacy benefit involves more than just PBM pricing. Utilization, Drug Mix, and Plan Design also impact the amount of money the Plan spends on their pharmacy...
The “Skinny” on Weight Loss Drugs
The “Skinny” on Weight Loss Drugs November 2023A lot of attention has been given lately to a new class of drugs called GLP-1’s. These drugs are increasingly being prescribed for type 2 diabetes and weight loss. Most Crystal Clear Rx clients cover these drugs for...
What to look for in a pharmacy benefit consultant
What to look for in a Pharmacy Benefit Consultant November 21, 2023Nobody wants to pay more than they should for any product or service. So, when many companies become concerned over pharmacy benefit costs, they may look for a Pharmacy Benefits Consultant or firm who...
Walgreens and CVS pharmacist Walk-outs
Walgreens and CVS pharmacist Walk-outs October 30th, 2023You may have recently seen news stories regarding pharmacist walk-outs at both Walgreens and CVS, and the potential for further work stoppages in the future at both of these companies, and potentially at other...
Choosing a PBM
Choosing a PBM September 2023 One of the primary services CCRx offers prospective clients is to assist them in the selection of a new pharmacy benefit manager, or PBM. Sometimes we are asked to utilize a Request for Proposal (RFP) process to narrow down the field of...
Effective Prior Authorization Management
Effective Prior Authorization Management August 2023 The effective management of the Prior Authorization (PA) function is a crucial aspect of healthcare that ensures patients receive the appropriate medications while controlling costs. Pharmacy Benefit Managers (PBMs)...
Conflict of Interest
Conflict of Interest July 2023 Recently a respected competitor published an article condemning most pharmacy benefit consultants for not disclosing conflicts of interest. They correctly pointed out that many big corporations such as “Boeing and UPS to local school...
New Transparency Models
New Transparency Models May 23, 2023 Both Express Scripts and OptumRx have announced new, optional Pass-Through pricing programs. Their clients can adopt this new pricing strategy, or they can continue with non-transparent pricing where the PBM won’t disclose the true...
Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company
Invokana Pricing slashed via The Mark Cuban Cost Plus Drug Company April 2023 The Mark Cuban Cost Plus Drug Company has announced that they have entered into a contract with JanssenUS, a subsidiary of Johnson and Johnson, to distribute Invokana, an important...